Welcome to the e-CCO Library!

DOP39: Utilization and sustainability of biologics in UC - A nationwide study from the epi-IIRN
Year: 2021
Source: ECCO'21 Virtual
Authors: Atia, O.(1); Yogev, D.(1); Friss, C.(1); Focht, G.(1); Orlanski-Meyer, E.(1); Magen Rimon, R.(2); Ledderman, N.(3); Greenfeld, S.(4); Kariv, R.(5); Loewenberg Weisband, Y.(6); Gabay, H.(6); Nevo, D.(7); Matz, E.(8); Gorelik, Y.(9); Chowers, Y.(9); Dotan, I.(10);Turner, D.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP40 Does levels of concerns and expectations predict IBD disease status?
Year: 2020
Source:

ECCO'20 Vienna

Authors:

V. Pittet, Swiss IBD Cohort Study

Created: Thursday, 30 January 2020, 10:12 AM
DOP40: Comorbidities and epidemiological risk factor but not immunosuppressive therapies increase the risk of COVID-19 in Inflammatory Bowel Disease (IBD): An ENEIDA-based, case-control study
Year: 2021
Source: ECCO'21 Virtual
Authors: Zabana Abdo, Y.(1,2);Marín-Jiménez, I.(3);Rodríguez-Lago, I.(4);Vera, I.(5);Martín, M.D.(6);Guerra, I.(7);Gisbert, J.P.(2,8);Mesonero, F.(9);Benítez, O.(1);Taxonera, C.(10);Ponferrada-Díaz, Á.(11);Piqueras, M.(12);Lucendo, A.(2,13);Caballol, B.(2,14);Mañosa, M.(2,15);Martínez-Montiel, P.(16);Bosca-Watts, M.(17);Gordillo, J.(18);Bujanda, L.(19);Manceñido, N.(20);Martínez-Pérez, T.(21);López, A.(22);Rodríguez, C.(23);García-López, S.(24);Vega, P.(25);Rivero, M.(26);Melcarne, L.(27);Calvo, M.(28);Iborra, M.(2,29);Barreiro-de Acosta, M.(30);Arias, L.(31);Barrio, J.(32);Pérez, J.L.(33);Busquets, D.(34);Pérez-Martínez, I.(35);Navarro-Llavat, M.(36);Hernández, V.(37);Argüelles-Arias, F.(38);Domènech, E.(2,15);Esteve, M.(1,2)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP40: Corticosteroid discontinuation and clinical outcomes in patients with moderately to severely active Crohn's disease treated with upadacitinib
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Dubinsky, M.C.(1)*;D'Haens, G.(2);Dewit, O.(3);Juillerat, P.(4);Panaccione, R.(5);Fujii, T.(6);Lacerda, A.P.(7);Dubcenco, E.(7);Anyanwu, S.(7);Doshi, C.(7);Mallick, M.(7);Garrison, A.(7);Liu, J.(7);Loftus Jr, E.V.(8);
Created: Friday, 14 July 2023, 10:43 AM
DOP40: Corticosteroid discontinuation and clinical outcomes in patients with moderately to severely active Crohn’s disease treated with upadacitinib
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Marla C Dubinsky
Created: Friday, 14 July 2023, 2:22 PM
DOP40: Does levels of concerns and expectations predict IBD disease status?
Year: 2020
Source: ECCO'20 Vienna
Authors: Valérie Pittet
Created: Tuesday, 23 June 2020, 5:40 PM
DOP40: Does levels of concerns and expectations predict IBD disease status?
Year: 2020
Source: ECCO'20 Vienna
Authors: Valérie Pittet
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP40: Effectiveness and safety of reference infliximab and biosimilar in Crohn’s disease: a French equivalence study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Meyer*1, J. Rudant2, J. Drouin2, A. Weill2, F. Carbonnel3, J. Coste2

Created: Friday, 22 February 2019, 9:41 AM
DOP40: Effectiveness and safety of reference infliximab and biosimilar in Crohn’s disease: a French equivalence study
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Antoine Meyer
Created: Tuesday, 28 May 2019, 3:32 PM
Anti-TNF agents, Biosimilars, Real world data
Files: 1
DOP40: Impact of corticosteroid usage on efficacy and safety outcomes in patients receiving upadacitinib for Ulcerative Colitis
Year: 2022
Source: ECCO'22
Authors: Raine, T.(1);Ishiguro, Y.(2);Rubin, D.(3);Finney-Hayward, T.(4);Dapo, I.(5);Phillips, C.(5);Cheng, E.(6);Targownik, L.(7);Loftus- Jr., E.V.(8);
Created: Friday, 11 February 2022, 3:52 PM
DOP40: Inflammatory Bowel Disease single cell atlas construction to enable cell type-specific target identification
Year: 2024
Source: ECCO'24 Stockholm
Authors: Corridoni, Daniele
Created: Tuesday, 30 April 2024, 5:03 PM
DOP41 Low-grade dysplasia prognosis and predictive factors for advanced neoplasia progression in the 21st century: A large multi-centre retrospective cohort study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Kabir1,2, K. Curtius3, I. Al-Bakir2,3,4, J. Hartono5, M. Johnson6, J.E. East6, J.O. Lindsay7,8, R. Vega9, S. Thomas-Gibson1,2, A. Hart2,4, T. Graham3, A. Wilson1,2

Created: Thursday, 30 January 2020, 10:12 AM
DOP41: Achievement of corticosteroid-free clinical endpoints in subjects with ulcerative colitis: an analysis of the phase 3 ELEVATE UC 52 trial
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Stefan Wolfgang Schreiber
Created: Friday, 14 July 2023, 2:22 PM
DOP41: Achievement of corticosteroid-free clinical endpoints in subjects with ulcerative colitis: an analysis of the phase 3 ELEVATE UC 52 trial
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Sands, B.E.(1);Rubin, D.T.(2);Panés, J.(3);Gecse, K.B.(4);Leung, Y.(5);Goetsch, M.(6);Wang, W.(7);Shan, K.(8);Woolcott, J.(9);Smith, C.C.(9);Wosik, K.(10);Schreiber, S.W.(11)*;
Created: Friday, 14 July 2023, 10:43 AM
DOP41: Efficacy and safety of extended induction treatment with upadacitinib 45 mg once daily followed by maintenance upadacitinib 15 or 30 mg once daily in patients with moderately to severely active Ulcerative Colitis
Year: 2022
Source: ECCO'22
Authors: Vermeire, S.(1);Danese, S.(2);Zhou, W.(3);Klaff, J.(3);Ilo, D.(3);Yao, X.(4);Levy, G.(5);Higgins, P.D.R.(6);Loftus- Jr., E.V.(7);Panaccione, R.(8);
Created: Friday, 11 February 2022, 3:52 PM
DOP41: Efficacy and safety of open-label treatment with tofacitinib 10 mg twice daily in patients with ulcerative colitis with clinical response, but not remission, after 52 weeks of maintenance therapy: data from the OCTAVE studies
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Chiorean1, C. Su2, K. Matsuoka3, A. Orlando4, A. J. Thorpe2, C. I. Nduaka2, D. S. Chapman5, D. A. Woodworth2, N. Lawendy2, G. S. Friedman2, R. D. Cohen*6

Created: Friday, 22 February 2019, 9:41 AM